Global Brain has invested in ThinkCyte K.K., a startup developing and commercializing AI-based innovative cell sorting platform

Global Brain has invested in ThinkCyte K.K. (ThinkCyte) through its KIRIN HEALTH INNOVATION FUND.

ThinkCyte is a startup working on the development of AI-based high-throughput cell sorting platform called “Ghost Cytometry” (GC). ThinkCyte’s initial product, the “VisionSort” platform, was commercially launched in June 2023. Powered by the company’s groundbreaking GC technology, “VisionSort” uses a combination of proprietary advanced optics, microfluidics, and AI to enable high-throughput, label-free, single cell analysis and sorting.

The platform has applications in several large life science markets including cell therapy, where it helps identify and isolate therapeutically valuable cells, and disease diagnostics where it can rapidly detect abnormal cells by morphology. Since the launch of “VisionSort,” the company has completed successful deliveries to major pharmaceutical companies, renowned research institutions, and biotech companies. ThinkCyte pursues the expansion to the global market by strengthening sales efforts and the delivery of new technologies to the life science market.

Global Brain has decided to invest in ThinkCyte because of its high-quality technology, great management team, and huge potential in the cell analyzing market. Through this investment, Global brain will contribute to the business expansion of ThinkCyte in collaboration with Kirin Holdings.